Editorial
doi: 10.1002/ddr.21652.
Epub 2020 Mar 3.
Alzheimer's disease: A need for personalized therapeutic approaches
Affiliations
- PMID: 32125005
- DOI: 10.1002/ddr.21652
Item in Clipboard
Editorial
Alzheimer's disease: A need for personalized therapeutic approaches
Drug Dev Res.
2020 Apr.
No abstract available
Similar articles
-
Phytoconstituents and their Possible Mechanistic Profile for Alzheimer's Disease - A Literature Review.Curr Drug Targets. 2019;20(3):263-291. doi: 10.2174/1389450119666180813095637. Curr Drug Targets. 2019. PMID: 30101703 Review.
-
Alzheimer's Disease: Advances in Drug Development.J Alzheimers Dis. 2018;65(1):3-13. doi: 10.3233/JAD-180145. J Alzheimers Dis. 2018. PMID: 30040716 Review.
-
Society for Neuroscience--38th Annual Meeting--Therapeutic approaches for Alzheimer's disease, schizophrenia and bipolar disorder.IDrugs. 2009 Jan;12(1):14-6. IDrugs. 2009. PMID: 19127498 No abstract available.
-
Early-onset Alzheimer's disease: a global cross-sectional analysis.Eur J Neurol. 2014 Sep;21(9):1149-54, e64-5. doi: 10.1111/ene.12453. Epub 2014 Apr 30. Eur J Neurol. 2014. PMID: 24780092
-
Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.Drugs Aging. 2004;21(6):395-403. doi: 10.2165/00002512-200421060-00004. Drugs Aging. 2004. PMID: 15084141
Cited by
-
Dendrimers in Alzheimer's Disease: Recent Approaches in Multi-Targeting Strategies.Pharmaceutics. 2023 Mar 10;15(3):898. doi: 10.3390/pharmaceutics15030898. Pharmaceutics. 2023. PMID: 36986759 Free PMC article. Review.
-
An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer's Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model.Int J Mol Sci. 2022 Aug 21;23(16):9449. doi: 10.3390/ijms23169449. Int J Mol Sci. 2022. PMID: 36012711 Free PMC article.
-
Microvascular Alterations in Alzheimer's Disease.Front Cell Neurosci. 2021 Jan 18;14:618986. doi: 10.3389/fncel.2020.618986. eCollection 2020. Front Cell Neurosci. 2021. PMID: 33536876 Free PMC article. Review.
-
Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.Pharmaceuticals (Basel). 2024 Apr 19;17(4):530. doi: 10.3390/ph17040530. Pharmaceuticals (Basel). 2024. PMID: 38675490 Free PMC article.
References
REFERENCES
-
- Brunden, K. R., Trojanowski, J. Q., & Lee, V. M. Y. (2009). Advances in Tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Reviews Drug Discovery, 8, 783-793.
-
- Chakravarty, H., Ju, Y., Chen, W. H., & Tam, K. Y. (2019). Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives. Drug Development Research. https://doi.org/10.1002/ddr.21631 [Epub ahead of print].
-
- Ciprés-Flores, F. J., Farfán-García, E. D., Andrade-Jorge, E., Cuevas-Hernández, R. I., Tamay-Cach, F., Martínez-Archundia, M., … Soriano-Ursúa, M. A. (2019). Identification of two arylimides as cholinesterase inhibitors and testing of propranolol addition on impaired rat memory. Drug Development Research. https://doi.org/10.1002/ddr.21633
-
- Davies, P., & Maloney, A. J. F. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. The Lancet, 308, 1403.
-
- De Strooper, B., Vassar, R., & Golde, T. (2010). The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nature Reviews Neurology. 6(2), 99-107. https://doi.org/10.1038/nrneurol.2009.218
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
